Nonalcoholic Steatohepatitis: A Review
- PMID: 32207804
- DOI: 10.1001/jama.2020.2298
Nonalcoholic Steatohepatitis: A Review
Erratum in
-
Typographical Error.JAMA. 2020 Apr 28;323(16):1619. doi: 10.1001/jama.2020.5249. JAMA. 2020. PMID: 32343314 No abstract available.
Abstract
Importance: Nonalcoholic steatohepatitis (NASH) is the inflammatory subtype of nonalcoholic fatty liver disease (NAFLD) and is associated with disease progression, development of cirrhosis, and need for liver transplant. Despite its importance, NASH is underrecognized in clinical practice.
Observations: NASH affects an estimated 3% to 6% of the US population and the prevalence is increasing. NASH is strongly associated with obesity, dyslipidemia, type 2 diabetes, and metabolic syndrome. Although a number of noninvasive tests and scoring systems exist to characterize NAFLD and NASH, liver biopsy is the only accepted method for diagnosis of NASH. Currently, no NASH-specific therapies are approved by the US Food and Drug Administration. Lifestyle modification is the mainstay of treatment, including dietary changes and exercise, with the primary goal being weight loss. Substantial improvement in histologic outcomes, including fibrosis, is directly correlated with increasing weight loss. In some cases, bariatric surgery may be indicated to achieve and maintain the necessary degree of weight loss required for therapeutic effect. An estimated 20% of patients with NASH will develop cirrhosis, and NASH is predicted to become the leading indication for liver transplants in the US. The mortality rate among patients with NASH is substantially higher than the general population or patients without this inflammatory subtype of NAFLD, with annual all-cause mortality rate of 25.56 per 1000 person-years and a liver-specific mortality rate of 11.77 per 1000 person-years.
Conclusions and relevance: Nonalcoholic steatohepatitis affects 3% to 6% of the US population, is more prevalent in patients with metabolic disease and obesity, progresses to cirrhosis in approximately 20% of cases, and is associated with increased rates of liver-specific and overall mortality. Early identification and targeted treatment of patients with nonalcoholic steatohepatitis are needed to improve patient outcomes, including directing patients toward intensive lifestyle modification to promote weight loss and referral for bariatric surgery as indicated for management of obesity and metabolic disease.
Comment in
-
Nonalcoholic Steatohepatitis.JAMA. 2020 Sep 1;324(9):899. doi: 10.1001/jama.2020.10434. JAMA. 2020. PMID: 32870291 No abstract available.
Similar articles
-
Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developments.Z Gastroenterol. 2019 Apr;57(4):508-517. doi: 10.1055/a-0784-8827. Epub 2019 Apr 9. Z Gastroenterol. 2019. PMID: 30965381 Review. English.
-
Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.Am J Gastroenterol. 2017 Apr;112(4):581-587. doi: 10.1038/ajg.2017.5. Epub 2017 Feb 14. Am J Gastroenterol. 2017. PMID: 28195177
-
[Overview of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Management].Yakugaku Zasshi. 2019;139(9):1147-1153. doi: 10.1248/yakushi.19-00011-1. Yakugaku Zasshi. 2019. PMID: 31474630 Review. Japanese.
-
The role of bariatric surgery in the management of nonalcoholic steatohepatitis.Curr Opin Gastroenterol. 2021 May 1;37(3):208-215. doi: 10.1097/MOG.0000000000000721. Curr Opin Gastroenterol. 2021. PMID: 33769376 Review.
-
The Future of Nonalcoholic Fatty Liver Disease Treatment.Med Clin North Am. 2019 Jan;103(1):57-69. doi: 10.1016/j.mcna.2018.08.005. Epub 2018 Nov 1. Med Clin North Am. 2019. PMID: 30466676 Review.
Cited by
-
Empagliflozin therapy and insulin resistance-associated disorders: effects and promises beyond a diabetic state.Arch Med Sci Atheroscler Dis. 2021 Apr 12;6:e57-e78. doi: 10.5114/amsad.2021.105314. eCollection 2021. Arch Med Sci Atheroscler Dis. 2021. PMID: 34027215 Free PMC article.
-
Mechanisms of nonalcoholic fatty liver disease and implications for surgery.Langenbecks Arch Surg. 2021 Feb;406(1):1-17. doi: 10.1007/s00423-020-01965-1. Epub 2020 Aug 24. Langenbecks Arch Surg. 2021. PMID: 32833053 Free PMC article. Review.
-
Protocols for Mitochondria as the Target of Pharmacological Therapy in the Context of Nonalcoholic Fatty Liver Disease (NAFLD).Methods Mol Biol. 2021;2310:201-246. doi: 10.1007/978-1-0716-1433-4_12. Methods Mol Biol. 2021. PMID: 34096005 Free PMC article. Review.
-
Non-alcoholic fatty liver disease (NAFLD) as a neglected metabolic companion of psychiatric disorders: common pathways and future approaches.BMC Med. 2020 Oct 1;18(1):261. doi: 10.1186/s12916-020-01713-8. BMC Med. 2020. PMID: 32998725 Free PMC article. Review.
-
Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?Int J Mol Sci. 2021 May 20;22(10):5375. doi: 10.3390/ijms22105375. Int J Mol Sci. 2021. PMID: 34065331 Free PMC article. Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical